<DOC>
	<DOCNO>NCT00026182</DOCNO>
	<brief_summary>Monoclonal antibody , rituximab , locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Interleukin-12 may kill cancer cell stop blood flow tumor stimulate person 's white blood cell kill cancer cell . Combining rituximab interleukin-12 may kill cancer cell . This randomized phase II trial compare well give rituximab together two different schedule interleukin-12 work treat patient B-cell non-Hodgkin lymphoma .</brief_summary>
	<brief_title>Rituximab Interleukin-12 Treating Patients With B-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare objective response patient B-cell non-Hodgkin 's lymphoma treat rituximab 2 different schedule interleukin-12* . II . Compare toxic effect regimens patient . III . Determine objective response rate patient mantle cell lymphoma treat regimen . IV . Determine overall progression-free survival patient treat regimen . V , Compare quality life patient treat regimen . NOTE : *Interleukin-12 longer available 6/30/05 . OUTLINE : This randomize , multicenter study . Patients stratify accord histology ( mantle cell lymphoma v [ close accrual 3/10/04 ] ) International Prognostic Factor Index ( low low-intermediate risk [ close accrual 3/10/04 ] v high-intermediate high risk ) . Patients randomize 1 2 treatment arm . ARM I : Patients receive rituximab IV day 1 , 8 , 15 , 22 . Patients receive interleukin-12* subcutaneously ( SC ) twice weekly begin day 2 continue disease progression . ARM II ( close accrual 11/14/03 ) : Patients receive rituximab arm I . Patients evaluate week 12 . Patients stable progressive disease receive interleukin-12* SC twice weekly disease progression 24 week . Patients complete partial response rituximab monitor disease progression begin interleukin-12 SC twice weekly disease progression . NOTE : *Interleukin-12 longer available 06/30/05 . Patients proceed follow-up outline . Quality life assess baseline 3 6 month . Patients follow every 3 month 1 year every 6 month 4 year . PROJECTED ACCRUAL : A total 90 patient ( 45 per treatment arm [ arm II close accrual 11/14/03 ] ) accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>Histologically confirm CD20positive Bcell nonHodgkin 's lymphoma Previously treat lowgrade lymphoma consider incurable standard therapy Grade I II follicular lymphoma* Lymphoplasmacytic lymphoma* Small lymphocytic lymphoma* Nodal marginal zone lymphoma* Extranodal marginal zone lymphoma MALT type* Splenic marginal zone lymphoma* Previously treat mantle cell lymphoma allow Meets one follow criterion measurable disease : Bidimensional diameter least 1.5 cm 1.5 cm physical exam At least 2 cm one dimension CT scan , MRI , plain radiograph image Palpable spleen least 5 cm leave costal margin No CNS involvement lymphoma Performance status ECOG 01 At least 12 week Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 75,000/mm^3 Hemoglobin ≥ 8 g/dL Bilirubin ≤ 3 time upper limit normal ( ULN ) AST ALT ≤ 3 time ULN Alkaline phosphatase ≤ 3 time ULN Creatinine ≤ 2 time ULN No New York Heart Association class III IV heart disease No history angina No uncontrolled peptic ulcer disease No uncontrolled infection No active malignancy No autoimmunerelated phenomenon ( e.g. , antinuclear antibody le 2 time ULN , rheumatoid factor le 2 time ULN , negative direct Coombs ) HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Prior stem cell transplantation allow More 12 month since prior rituximab No prior interleukin12 No concurrent immunotherapy Recovered prior chemotherapy No concurrent chemotherapy No concurrent steroid therapy No concurrent radiotherapy Any number prior therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>